A study showed that survivors of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) had an increased risk for cardiovascular morbidity and mortality, which peaked within the first ...
First identified by Stevens and Johnson in 1922, SJS and TEN are now recognized as disorders with a continuum of severity, from milder forms (SJS) to the most severe (TEN). SJS/TEN is associated with ...
A collaborative research group has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous adverse reactions such as Stevens–Johnson syndrome (SJS) and toxic ...
Use of enfortumab vedotin (Padcev), which was approved less than 2 years ago for the treatment of metastatic urothelial cancer, has been associated with cases of Stevens-Johnson syndrome (SJS) and ...
The retrospective study of patient hospital data showed that current approaches to identifying a culprit drug often overidentify drugs unlikely to be responsible for Stevens-Johnson syndrome/toxic ...
First identified by Stevens and Johnson in 1922, SJS and TEN are now recognized as disorders with a continuum of severity, from milder forms (SJS) to the most severe (TEN). SJS/TEN is associated with ...
This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does not include a full text component.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results